KalVista Pharmaceuticals 将来の成長

Future 基準チェック /56

KalVista Pharmaceuticalsは、61.3%と52.4%でそれぞれ年率61.3%で利益と収益が成長すると予測される一方、EPSはgrowで63.5%年率。

主要情報

61.3%

収益成長率

63.5%

EPS成長率

Biotechs 収益成長	28.5%
収益成長率	52.4%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	04 Nov 2024

今後の成長に関する最新情報

Recent updates

KalVista: Upcoming PDUFA, But Not Without Risks

Nov 25

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?

Sep 12

KalVista Pharmaceuticals: Looking To Be A Major Player In HAE

Sep 05

Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch

Jun 24

KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)

Feb 14

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Jan 30

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Oct 04

We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully

May 02

KalVista: Another Setback But The Key Value Driver Is Still In Place

Oct 14

Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

Sep 24

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?

May 18

Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth

Feb 02

We Discuss Why KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Compensation May Be Closely Reviewed

Sep 24

We're Hopeful That KalVista Pharmaceuticals (NASDAQ:KALV) Will Use Its Cash Wisely

Jul 02

業績と収益の成長予測

NasdaqGM:KALV - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
4/30/2027	174	-7	-48	23	5
4/30/2026	80	-109	-141	-93	7
4/30/2025	20	-155	-170	-151	7
7/31/2024	N/A	-142	-103	-103	N/A
4/30/2024	N/A	-127	-90	-89	N/A
1/31/2024	N/A	-108	-97	-97	N/A
10/31/2023	N/A	-101	-79	-78	N/A
7/31/2023	N/A	-95	-80	-79	N/A
4/30/2023	N/A	-93	-76	-75	N/A
1/31/2023	N/A	-91	-81	-79	N/A
10/31/2022	N/A	-92	-86	-84	N/A
7/31/2022	N/A	-89	-85	-83	N/A
4/30/2022	N/A	-82	-79	-78	N/A
1/31/2022	N/A	-73	-63	-62	N/A
10/31/2021	N/A	-61	-57	-56	N/A
7/31/2021	N/A	-52	-45	-44	N/A
4/30/2021	N/A	-46	-30	-30	N/A
1/31/2021	4	-38	-32	-32	N/A
10/31/2020	5	-37	-37	-37	N/A
7/31/2020	9	-33	-37	-37	N/A
4/30/2020	13	-29	-45	-45	N/A
1/31/2020	12	-31	-43	-43	N/A
10/31/2019	14	-26	-41	-40	N/A
7/31/2019	16	-23	-42	-41	N/A
4/30/2019	16	-21	-37	-36	N/A
1/31/2019	18	-13	-34	-32	N/A
10/31/2018	16	-14	5	7	N/A
7/31/2018	12	-16	7	9	N/A
4/30/2018	8	-16	N/A	11	N/A
1/31/2018	4	-19	N/A	14	N/A
10/31/2017	2	-22	N/A	-26	N/A
7/31/2017	1	-21	N/A	-23	N/A
4/30/2017	2	-21	N/A	-24	N/A
1/31/2017	2	-23	N/A	-23	N/A
10/31/2016	2	-18	N/A	-15	N/A
7/31/2016	2	-18	N/A	-15	N/A
4/30/2016	2	-15	N/A	-13	N/A
4/30/2015	2	-9	N/A	-6	N/A

アナリストによる今後の成長予測

収入対貯蓄率: KALVは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: KALV今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: KALV今後 3 年以内に収益を上げることが予想されます。

収益対市場: KALVの収益 ( 52.4% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: KALVの収益 ( 52.4% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: KALVの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

KalVista Pharmaceuticals 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2027

Price target increased by 7.6% to US$20.80

Consensus revenue estimates fall by 58%

Price target decreased to US$21.83

Price target decreased to US$32.83

No longer forecast to breakeven

Recent updates

KalVista Pharmaceuticals, Inc. Appoints Laurence Reid to Board of Directors

KalVista: Upcoming PDUFA, But Not Without Risks

KalVista Pharmaceuticals, Inc. announced that it expects to receive $5 million in funding from DRI Capital Inc.

KalVista Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $55 million.

KalVista Pharmaceuticals, Inc. Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology

KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?

KalVista Pharmaceuticals: Looking To Be A Major Player In HAE

Kalvista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

KalVista Pharmaceuticals, Inc., Annual General Meeting, Oct 03, 2024

KalVista Pharmaceuticals, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Initiates KONFident-KID Trial for On-Demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11

Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch

KalVista Pharmaceuticals, Inc. Submits New Drug Application to FDA for Sebetralstat as First Oral On-Demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Presents Data At Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024

Kalvista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema At the European Academy of Allergy and Clinical Immunology (Eaaci) Congress 2024

Kalvista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating Its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema

CEO & Director exercised options and sold US$258k worth of stock

Forecast to breakeven in 2027

Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors

KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals, Inc. Announces Board Changes

New minor risk - Share price stability

CEO & Director exercised options and sold US$351k worth of stock

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

New minor risk - Shareholder dilution

CEO & Director recently sold US$876k worth of stock

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

KalVista Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $160.125 million.

KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)

Kalvista Pharmaceuticals, Inc. Reports Phase 3 Konfident Trial Meets All Endpoints for Sebetralstat as First Oral On-Demand Therapy for Hereditary Angioedema

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

New major risk - Financial position

CEO & Director exercised options and sold US$122k worth of stock

Price target increased by 7.6% to US$20.80

Kalvista Pharmaceuticals Announces Phase 3 Konfident Trial Milestone Achieved

KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Independent Director notifies of intention to sell stock

CEO & Director exercised options and sold US$160k worth of stock

KalVista Pharmaceuticals, Inc., Annual General Meeting, Sep 26, 2023

KalVista Pharmaceuticals, Inc. Appoints Nicole Sweeny as Chief Commercial Officer

Consensus revenue estimates fall by 58%

KalVista Pharmaceuticals, Inc. Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology

CEO & Director exercised options and sold US$57k worth of stock

KalVista Pharmaceuticals, Inc. Presents Data At 13Th C1-Inhibitor Deficiency & Angioedema Workshop

We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully

KalVista Pharmaceuticals, Inc. Provides Progress Updates on Sebetralstat Development

Kalvista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in the Lancet

Kalvista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President

Price target decreased to US$21.83

KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting

Kalvista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Announces Management Changes

KalVista: Another Setback But The Key Value Driver Is Still In Place

KalVista Pharmaceuticals, Inc. Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop

KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema

Price target decreased to US$32.83

Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

CEO & Director notifies of intention to sell stock

KalVista Pharmaceticals GAAP EPS of -$0.94

Kalvista Pharmaceuticals, Inc. Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema